One Turn Open the globe →Globe →

Health · Washington, United States · United States of America ·

US FDA rejects China lung cancer drug

The FDA rejected ivonescimab, a closely watched lung cancer drug from China. It had become a symbol of China's rise in drug development.

Why it matters

It affects Chinese drugmakers' hopes in the US market.

Background

The drug targets lung cancer.

The story so far

  1. US FDA rejects China lung cancer drug
  2. FDA rejects China's lung cancer drug ivonescimab

Follow the whole story →

Sources

This summary was written automatically from the reporting linked above; follow the sources for the full story. How One Turn works.

See it on the globe →All of Nov 15's stories

More on health